Frederick Askari, MD, PhD

The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope

In the final episode, 'The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope,' the panelists explore the evolving landscape of long-term care coordination and the resources available to improve patient outcomes. Dr. Peter Hedera and Dr. Rima Fawaz emphasize the value of the Center of Excellence (COE) model, which functions as a "one-stop clinic" where hepatology and neurology are integrated to reduce the travel and appointment burden on families. They clarify that these centers should act as partners in care, providing consultative guidance to local primary care providers and gastroenterologists rather than replacing them.

A significant portion of the discussion focuses on the critical role of patient advocacy, particularly the Wilson Disease Association. The panel highlights how these organizations provide essential resources, connecting patients with peers who can offer real-world encouragement and technical advice on managing the disease. This support network, combined with the use of specialty pharmacies to track prescription fills, creates a multi-layered safety net that helps prevent patients from falling through the cracks of the healthcare system.

The experts conclude the series with a message of profound hope. While acknowledging persistent unmet needs in diagnostic monitoring and adherence, they point to a "bright future" driven by next-generation chelators and the long-term promise of gene editing. They leave clinicians and caregivers with the encouraging reminder that with early diagnosis, strict adherence, and modern multidisciplinary support, patients with Wilson disease can lead full, professional, and socially fulfilling lives—pushing the disease "to the back burner" for decades to come.

Thank you for watching this Peer Exchange series on Wilson disease. Please subscribe to our newsletter for information on upcoming video series.

Videos

Clinicians share practical ways to boost lifelong Wilson disease treatment adherence—education, monitoring, and team-based transition support.

The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease

In 'The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease,' our panel delves into the human elements of lifelong disease management. Dr. Peter Hedera emphasizes that clinicians can "never rest on their laurels," even with well-controlled patients, as adherence is a never-ending battle influenced by life stressors and "treatment burnout." He advocates for a tailored approach that uses objective laboratory evidence—such as shifting copper levels—to non-confrontationally re-engage patients who may be skipping doses.

Dr. Rima Fawaz highlights the high-risk period of transitioning from adolescent to adult care. She shares the Yale model’s success in creating a seamless transition through the Wilson Disease Registry, where patients often encounter the same core team across life stages. The discussion underscores that pediatric adherence is frequently driven by parents, but as patients enter young adulthood, the focus must shift to direct patient education regarding the specific mechanisms of their medication, such as why zinc must be taken away from food to remain effective.

The panel also explores the "team effort" required to maintain compliance, involving social workers, nutritionists, and medication access specialists who navigate insurance and prior authorizations. Dr. Hedera adds that health psychology and even visual aids—such as showing patients videos of their own prior symptoms—can be powerful tools for reinforcing the necessity of therapy without relying solely on fear. The experts conclude that a proactive, multidisciplinary system that tracks follow-up appointments and lab work is the most effective way to ensure long-term clinical success.

Our next episode, 'The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope,' further explores Wilson disease, highlighting the essential role of multidisciplinary collaboration and patient advocacy organizations. The experts discuss the clinical "one-stop-shop" model, the importance of referring to centers of excellence, and the optimistic future of treatment as research advances toward potentially curative genetic therapies.

Explore why Wilson’s disease patients stop lifelong therapy and how simpler, better-tolerated dosing improves adherence, preventing relapse and severe liver outcomes.

Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease

In this episode, 'Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease,' the experts explore the complexities of maintaining treatment compliance in a lifelong chronic condition. Dr. Rima Fawaz addresses the "grave and irreversible" consequences of non-adherence, particularly for patients with neurological presentations. She notes a unique challenge in hepatic-focused cases, where a lack of daily symptoms can lead to a false sense of security, resulting in treatment gaps that may eventually trigger acute liver failure or decompensation. The panel specifically identifies the "desire to be normal" as a major hurdle for pediatric and adolescent patients, who often struggle with dietary restrictions and the social stigma of frequent medication.

The discussion shifts to a review of data from the AASLD Liver Meeting, which demonstrated a high medication adherence rate (84% of days covered) for patients treated with trientine tetrahydrochloride. Dr. Peter Hedera emphasizes that these findings are "data-driven" evidence that convenience directly correlates with clinical success. He highlights that removing technical barriers—such as the need for refrigeration or the shift from thrice-daily to twice-daily dosing—provides tangible benefits for students and active adults.

Concluding the segment, the panelists reflect on the psychological components of adherence, noting that even patients with medical backgrounds can relapse if they stop treatment because they "feel okay." The experts agree that while clinical trials establish efficacy, real-world evidence is essential for understanding how subtle changes in drug formulation can lead to profound improvements in long-term patient stability and quality of life.

The next episode in this series, 'The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease,' features the panelists advancing their conversation on Wilson disease and focusing on the essential role of longitudinal education. The experts discuss tailored counseling strategies to combat treatment burnout, the logistical hurdles of transitioning from pediatric to adult care, and how center-of-excellence models utilize multidisciplinary teams to prevent patients from falling through the cracks.

New ATP7B gene therapies aim to normalize copper in Wilson’s disease, reducing chelation needs while raising durability and patient-selection questions.

Gene Therapy as an Emerging Treatment Approach in Wilson Disease

This episode, titled 'Gene Therapy as an Emerging Treatment Approach in Wilson Disease,' features panelists discussing the revolutionary potential of UX701 and other AAV-based gene therapies. Dr. Peter Hedera explains that because carriers of a single ATP7B mutation are asymptomatic, a treatment does not need to achieve 100% expression to restore functional copper homeostasis. However, he raises critical questions regarding the durability of these benefits, noting that because hepatocytes are dividing cells, there is a risk of losing the genetic construct over time. Furthermore, the immunogenicity of adeno-associated viruses (AAV) typically limits patients to a single "one-shot" treatment, making durability the primary focus of current clinical trials.

The conversation expands into next-generation technologies like CRISPR-Cas9 and prime editing. While these tools offer the possibility of permanent genetic correction, the experts acknowledge the immense challenge posed by the high number of unique ATP7B mutations. The panelists emphasize that the future of Wilson disease management will likely move away from a "one size fits all" model toward a highly individualized approach. This could involve tailoring choices between traditional chelation, once-daily salts, or gene therapy based on a patient's lifestyle, their ability to adhere to complex regimens, and their willingness to undergo short-term immunosuppression for long-term freedom from daily pills.

As the segment concludes, the panel highlights that while current trials often focus on stable patients, future research may investigate whether gene therapy can accelerate recovery in acutely ill or non-compliant populations. The experts look forward to real-world evidence to determine if these emerging therapies will act as standalone cures or be integrated into hybrid treatment plans, marking an era of unprecedented granular control in medical genetics.

In the next episode, 'Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the critical barriers to lifelong medication compliance. The experts examine recent real-world data regarding treatment discontinuation and discuss how practical factors—such as dosing frequency and storage requirements—significantly influence clinical outcomes and disease progression.

Frederick Askari, MD, PhD

Articles